Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer
Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.
Authors
- Meggy Suarez‐Carmona (ORCID: https://orcid.org/0000-0002-8892-1546)
- Niels Halama (ORCID: https://orcid.org/0000-0003-0344-6027)
Institutions
- German Cancer Research Center (DE)
- Johannes Gutenberg University Mainz (DE)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
Publication Details
- Journal
- Trends in cancer
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1016/j.trecan.2024.10.006
- Citations
- 3
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.85
Funders
- Deutsches Krebsforschungszentrum